A Single Treatment Pharmacokinetic and Safety Study of Natroba (Spinosad) Topical Suspension 0.9% w/w in Subjects 1 Month to 3 Years 11 Months of Age With an Active Scabies Infestation
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Spinosad (Primary)
- Indications Scabies
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Cipher Pharmaceuticals; ParaPRO
- 27 Nov 2023 Status changed from active, no longer recruiting to recruiting.
- 17 Oct 2023 The protocol has been amended to change in Blood samples collection period up to 3 hours post treatment.
- 17 Oct 2023 Planned End Date changed from 30 Jun 2023 to 31 Mar 2026.